These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36738834)

  • 21. Use of glucometer and fasting blood glucose as screening tools for diabetes mellitus type 2 and glycated haemoglobin as clinical reference in rural community primary care settings of a middle income country.
    Muktabhant B; Sanchaisuriya P; Sarakarn P; Tawityanon W; Trakulwong M; Worawat S; Schelp FP
    BMC Public Health; 2012 May; 12():349. PubMed ID: 22583817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using glycated haemoglobin testing to simplify diabetes screening in remote Aboriginal Australian health care settings.
    Marley JV; Oh MS; Hadgraft NT; Singleton SL; Isaacs K; Atkinson DN
    Med J Aust; 2015 Jul; 203(1):28-32. PubMed ID: 26126564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential screening for diabetes--evaluation of a campaign in Swiss community pharmacies.
    Hersberger KE; Botomino A; Mancini M; Bruppacher R
    Pharm World Sci; 2006 Jun; 28(3):171-9. PubMed ID: 17004016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opportunistic screening for type 2 diabetes in community pharmacies. Results from a region-wide experience in Italy.
    Gnavi R; Sciannameo V; Baratta F; Scarinzi C; Parente M; Mana M; Giaccone M; Cavallo Perin P; Costa G; Spadea T; Brusa P
    PLoS One; 2020; 15(3):e0229842. PubMed ID: 32187210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient acceptability of targeted risk-based detection of non-communicable diseases in a dental and pharmacy setting.
    Yonel Z; Yahyouche A; Jalal Z; James A; Dietrich T; Chapple ILC
    BMC Public Health; 2020 Oct; 20(1):1576. PubMed ID: 33081745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of a New Opportunistic Screening Strategy for Walk-in Fingertip HbA
    Shono A; Kondo M; Hoshi SL; Okubo R; Yahagi N
    Diabetes Care; 2018 Jun; 41(6):1218-1226. PubMed ID: 29686159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diabetes risk assessments and HbA1c-measurements in community pharmacies.
    Risøy AJ; Kjome RLS; Sandberg S; Sølvik UØ
    Int J Pharm Pract; 2023 Sep; 31(5):512-519. PubMed ID: 37527496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Point-of-care testing of HbA1c and blood glucose in a remote Aboriginal Australian community.
    Martin DD; Shephard MD; Freeman H; Bulsara MK; Jones TW; Davis EA; Maguire GP
    Med J Aust; 2005 May; 182(10):524-7. PubMed ID: 15896181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening for type 2 diabetes and impaired glucose metabolism: the Australian experience.
    Colagiuri S; Hussain Z; Zimmet P; Cameron A; Shaw J;
    Diabetes Care; 2004 Feb; 27(2):367-71. PubMed ID: 14747215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of point of care testing on diabetes services along Victoria's Mallee Track: results of a community-based diabetes risk assessment and management program.
    Shephard MD; Mazzachi BC; Shephard AK; McLaughlin KJ; Denner B; Barnes G
    Rural Remote Health; 2005; 5(3):371. PubMed ID: 16026194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of Prediabetes and Undiagnosed Diabetes in Canada (2007-2011) According to Fasting Plasma Glucose and HbA1c Screening Criteria.
    Rosella LC; Lebenbaum M; Fitzpatrick T; Zuk A; Booth GL
    Diabetes Care; 2015 Jul; 38(7):1299-305. PubMed ID: 25852207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of screening methods for sleep disorders in Australian community pharmacies: a randomized controlled trial.
    Fuller JM; Wong KK; Grunstein R; Krass I; Patel J; Saini B
    PLoS One; 2014; 9(6):e101003. PubMed ID: 24978952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of glucose metabolism in polycystic ovary syndrome: HbA1c or fasting glucose compared with the oral glucose tolerance test as a screening method.
    Lerchbaum E; Schwetz V; Giuliani A; Obermayer-Pietsch B
    Hum Reprod; 2013 Sep; 28(9):2537-44. PubMed ID: 23756702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-sectional comparison of point-of-care with laboratory HbA₁c in detecting diabetes in real-world remote Aboriginal settings.
    Marley JV; Oh MS; Hadgraft N; Singleton S; Isaacs K; Atkinson D
    BMJ Open; 2015 Mar; 5(3):e006277. PubMed ID: 25765020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis.
    Jalkanen K; Aarnio E; Lavikainen P; Lindström J; Peltonen M; Laatikainen T; Martikainen J
    BMC Health Serv Res; 2021 Sep; 21(1):916. PubMed ID: 34482831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of undiagnosed type 2 diabetes in patients admitted with acute coronary syndrome: the utility of easily reproducible screening methods.
    Karamat MA; Raja UY; Manley SE; Jones A; Hanif W; Tahrani AA
    BMC Endocr Disord; 2017 Jan; 17(1):3. PubMed ID: 28143538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementation of point-of-care HbA1C instruments into community pharmacies: Initial development of a pathway for robust community testing.
    Radley A; Beer L; Rushdi D; Close H; McBurney S; Mackenzie A; Gourlay A; Barnett A; Grant A; Greig N; Dow E; Sutherland C
    Ann Clin Biochem; 2023 Dec; ():45632231219380. PubMed ID: 37996254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Point-of-care HbA1c screening predicts diabetic status of dental patients.
    Franck SD; Stolberg RL; Bilich LA; Payne LE
    J Dent Hyg; 2014 Feb; 88(1):42-52. PubMed ID: 24563052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening.
    Webb DR; Khunti K; Srinivasan B; Gray LJ; Taub N; Campbell S; Barnett J; Henson J; Hiles S; Farooqi A; Griffin SJ; Wareham NJ; Davies MJ
    Trials; 2010 Feb; 11():16. PubMed ID: 20170482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.